Refine by
Vaccine Response Articles & Analysis
45 news found
As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research excitement around cancer vaccines. "Think of vaccines as a training camp for the immune system," says a scientist at Creative Biolabs, a US-based ...
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
In another study published in the Journal of Drug Delivery Science and Technology, researchers investigated and revealed that the coated microneedles were able to efficiently deliver the vaccine, eliciting a robust immune response in animal models. This exciting development could revolutionize the way vaccines are administered, making ...
Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. ...
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European Vaccine Initiative ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex antigens and create more scalable and ...
The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. ...
Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline Next steps : Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022 ...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been ...
Early signs of clinical activity were observed with encouraging ongoing anti-tumor activity in the first patients under neoantigen vaccine treatment. Manufacturing time and drug release were compatible with the clinical treatment protocols. ...
The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab™ and AvidiMab® for antibodies. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous ...
ByScancell
Highly effective vaccines providing robust protection to people remains to be an unmet need. ...
ByScancell
These changes are associated with increased infectivity and confer the potential to evade the host antibody immune response induced by previous vaccinations or infections (“escape mutations”). While Omicron is relatively less pathogenic than previous variants like Delta, it remains a lethal threat to those patients who cannot be ...
“Our PCV franchise is designed to improve upon the standard-of-care pneumococcal vaccines by covering the serotypes that are responsible for most of the residual pneumococcal disease currently in ...
(Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing ...
The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region. ...
(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that data analyzing immune response following two doses of the vaccine candidate, COVAXIN™ (BBV152), from a third-party study were published on the preprint server, medRxiv. The data compared the ...
"Testing is a critical component of keeping schools open, even as vaccines are approved for new age groups," said Manoj Gandhi, M.D., Ph.D., senior medical director at Thermo Fisher Scientific. ...
INOVIO plans to test clinical samples from our INO-4800 vaccine candidate as well as our Pan-COVID-19 vaccine candidate INO-4802 against the Omicron variant to assess the generation of immune responses, with data expected in the coming weeks. ...
Secondary endpoints include biological activity of the therapeutic vaccine TG4050. CELLULAR IMMUNE RESPONSE WAS EVALUABLE FOR 4 OF THE PATIENTS TREATED WITH TG4050. ...